• Double Bond Pharmaceutical International AB issued a correction to its release on SI053 (Temodex) being accepted for presentation at the 2026 SNO Annual Meeting.
• The amendment removed an incorrectly included MAR label.
• The underlying announcement remains that clinical real-world evidence data for SI053 will be presented in Philadelphia on Nov. 12-15, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Double Bond Pharmaceutical International AB published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.